These findings demonstrate that Fc engineering of avelumab can substantially augment ADCC and CDC activity against PD-L1+ tumors. However, the enhanced effector function of AveFc5M led to NK cell fratricide, potentially limiting NK cell-dominated anti-cancer responses.

9 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

FCGR3A (Fc Fragment Of IgG Receptor IIIa)

Bavencio (avelumab)

13d

Case Report: Complete metabolic responses to trastuzumab-deruxtecan in HER2-altered solid tumors: two illustrative cases. (PubMed, Front Immunol)

The second case involves a patient with metastatic micropapillary urothelial carcinoma with HER2 expression, refractory to platinum chemotherapy, avelumab maintenance, and enfortumab vedotin. These two observations illustrate the capacity of T-DXd to induce deep and complete metabolic remissions in distinct HER2-altered solid tumors. They support further development of HER2-targeted ADCs beyond traditional indications and highlight the value of FDG-PET/CT for assessing the depth of response to these agents.

13 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

HER-2 (Human epidermal growth factor receptor 2)

HER-2 amplification • HER-2 mutation • HER-2 expression • HER-2 exon 20 insertion • HER-2 exon 20 mutation

Enhertu (fam-trastuzumab deruxtecan-nxki) • Bavencio (avelumab) • Padcev (enfortumab vedotin-ejfv)

15d

MS100070_0087: Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors (clinicaltrials.gov)

P1, N=17, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Sep 2026 --> May 2026 | Trial primary completion date: Sep 2026 --> Feb 2026

15 days ago

Trial completion date • Trial primary completion date

Lenvima (lenvatinib) • Bavencio (avelumab)

17d

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (clinicaltrials.gov)

P1/2, N=90, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027

17 days ago

Trial completion date • Trial primary completion date

Bavencio (avelumab) • peposertib (M3814) • Xofigo (radium Ra-223 dichloride)

24d

A Prospective, Multicenter Clinical Study of Avelumab (PD-L1) Combined with Short-Course Radiotherapy and Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer (ChiCTR2600121263)

P=N/A, N=270, Provincial Hospital Affiliated to Shandong First Medical University; Provincial Hospital Affiliated to Shandong First Medical University

24 days ago

New trial

MSI (Microsatellite instability)

Tecentriq (atezolizumab) • Bavencio (avelumab)

24d

Evaluation of the efficacy and safety of avelumab in combination with albumin-bound paclitaxel, bevacizumab and radiotherapy for second-line or later treatment of advanced extrapulmonary neuroendocrine carcinoma: A single-arm, open-label, prospective clinical study (ChiCTR2600117826)

P2, N=30, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

24 days ago

New P2 trial

Avastin (bevacizumab) • Bavencio (avelumab) • albumin-bound paclitaxel

29d

Avelumab has the highest risk of IRRs followed by atezolizumab and dual ICIs. This comparative study provides insight into the incidence of IRRs with ICI regimens. These results are useful in assessing which systemic therapies are responsible for IRRs, particularly when ICIs are combined with other agents.

29 days ago

Retrospective data • Review • Journal • Checkpoint inhibition

LAG3 (Lymphocyte Activating 3)

Opdivo (nivolumab) • Tecentriq (atezolizumab) • Bavencio (avelumab) • relatlimab (BMS-986016)

30d

InCITe: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (clinicaltrials.gov)

P2, N=145, Active, not recruiting, Laura Huppert, MD, BA | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Jan 2027

30 days ago

Enrollment closed • Trial completion date • Trial primary completion date • Tumor mutational burden

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 negative

Bavencio (avelumab) • Mektovi (binimetinib) • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma (clinicaltrials.gov)

P2, N=25, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

1 month ago

Trial initiation date

PD-L1 (Programmed death ligand 1)

Bavencio (avelumab) • Padcev (enfortumab vedotin-ejfv)

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (clinicaltrials.gov)

P2/3, N=956, Active, not recruiting, BicycleTx Limited | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed

Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Bavencio (avelumab) • zelenectide pevedotin (BT8009)